Obesity and type 2 diabetes continue to pose urgent challenges worldwide, with hundreds of millions of adults struggling with excess weight. Recent clinical studies[1] have highlighted tirzepatide, a next-generation dual GLP-1 and GIP receptor agonist, as a significant advancement. Its proven impact on significant weight reduction and enhanced glucose regulation marks a new era in […]